| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cesarean Section | 26 | 2020 | 112 | 7.110 |
Why?
|
| Premature Birth | 20 | 2020 | 67 | 3.810 |
Why?
|
| Pregnancy | 109 | 2020 | 996 | 3.760 |
Why?
|
| Pregnancy Complications | 18 | 2017 | 105 | 3.510 |
Why?
|
| Obesity, Morbid | 8 | 2017 | 73 | 2.830 |
Why?
|
| Pregnancy Outcome | 30 | 2020 | 90 | 2.320 |
Why?
|
| Vaginal Birth after Cesarean | 23 | 2014 | 26 | 1.960 |
Why?
|
| Infant Mortality | 8 | 2020 | 23 | 1.680 |
Why?
|
| Uterine Rupture | 16 | 2014 | 18 | 1.640 |
Why?
|
| Adult | 83 | 2020 | 9375 | 1.600 |
Why?
|
| Cerebral Palsy | 4 | 2016 | 62 | 1.590 |
Why?
|
| Surgical Wound Infection | 6 | 2016 | 84 | 1.560 |
Why?
|
| Female | 119 | 2020 | 19999 | 1.470 |
Why?
|
| Retrospective Studies | 53 | 2020 | 3505 | 1.470 |
Why?
|
| Pre-Eclampsia | 11 | 2020 | 66 | 1.460 |
Why?
|
| Obesity | 7 | 2017 | 1176 | 1.450 |
Why?
|
| Endometritis | 4 | 2015 | 5 | 1.420 |
Why?
|
| Infant, Newborn | 26 | 2020 | 673 | 1.370 |
Why?
|
| Ultrasonography, Prenatal | 18 | 2013 | 42 | 1.250 |
Why?
|
| Magnesium Sulfate | 5 | 2016 | 14 | 1.230 |
Why?
|
| Body Mass Index | 9 | 2020 | 923 | 1.200 |
Why?
|
| Humans | 122 | 2020 | 32082 | 1.180 |
Why?
|
| Neuroprotective Agents | 3 | 2016 | 27 | 1.120 |
Why?
|
| Cohort Studies | 36 | 2020 | 1816 | 1.090 |
Why?
|
| Fetal Growth Retardation | 15 | 2020 | 34 | 1.080 |
Why?
|
| Trial of Labor | 13 | 2014 | 19 | 1.080 |
Why?
|
| Obstetric Labor Complications | 6 | 2019 | 18 | 1.040 |
Why?
|
| Young Adult | 26 | 2020 | 2665 | 1.010 |
Why?
|
| Labor, Induced | 5 | 2019 | 17 | 0.980 |
Why?
|
| Postoperative Complications | 6 | 2017 | 780 | 0.980 |
Why?
|
| Gestational Age | 21 | 2019 | 121 | 0.910 |
Why?
|
| Logistic Models | 15 | 2019 | 783 | 0.890 |
Why?
|
| Postpartum Hemorrhage | 3 | 2020 | 18 | 0.880 |
Why?
|
| Cost-Benefit Analysis | 7 | 2018 | 185 | 0.770 |
Why?
|
| Morbidity | 4 | 2019 | 98 | 0.730 |
Why?
|
| Infant, Premature, Diseases | 2 | 2019 | 25 | 0.720 |
Why?
|
| Decision Support Techniques | 10 | 2020 | 128 | 0.710 |
Why?
|
| Risk Factors | 31 | 2020 | 3880 | 0.700 |
Why?
|
| Patient Admission | 2 | 2017 | 58 | 0.690 |
Why?
|
| Surgical Wound Dehiscence | 3 | 2015 | 13 | 0.670 |
Why?
|
| Cervical Length Measurement | 2 | 2016 | 2 | 0.660 |
Why?
|
| Chorioamnionitis | 1 | 2019 | 10 | 0.650 |
Why?
|
| Case-Control Studies | 16 | 2020 | 895 | 0.640 |
Why?
|
| Sterilization, Tubal | 1 | 2018 | 3 | 0.640 |
Why?
|
| Hematoma | 2 | 2015 | 27 | 0.630 |
Why?
|
| Fetal Macrosomia | 2 | 2016 | 5 | 0.620 |
Why?
|
| Risk Assessment | 17 | 2020 | 1427 | 0.610 |
Why?
|
| Cesarean Section, Repeat | 9 | 2017 | 10 | 0.600 |
Why?
|
| Ovarian Neoplasms | 1 | 2018 | 96 | 0.590 |
Why?
|
| Negative-Pressure Wound Therapy | 1 | 2017 | 35 | 0.580 |
Why?
|
| Polyhydramnios | 2 | 2016 | 2 | 0.560 |
Why?
|
| Cervix Uteri | 1 | 2016 | 28 | 0.550 |
Why?
|
| Intraoperative Complications | 1 | 2017 | 56 | 0.550 |
Why?
|
| United States | 16 | 2020 | 3975 | 0.540 |
Why?
|
| Multivariate Analysis | 13 | 2019 | 684 | 0.500 |
Why?
|
| Delivery, Obstetric | 6 | 2019 | 58 | 0.490 |
Why?
|
| Fetal Distress | 1 | 2014 | 3 | 0.480 |
Why?
|
| Periodontal Diseases | 3 | 2010 | 17 | 0.460 |
Why?
|
| Postural Balance | 1 | 2016 | 182 | 0.450 |
Why?
|
| Oxytocin | 5 | 2020 | 28 | 0.440 |
Why?
|
| Pregnancy, Multiple | 3 | 2010 | 10 | 0.440 |
Why?
|
| Pesticides | 1 | 2016 | 199 | 0.440 |
Why?
|
| Occupational Exposure | 1 | 2016 | 232 | 0.430 |
Why?
|
| Magnesium | 2 | 2015 | 30 | 0.420 |
Why?
|
| Emigrants and Immigrants | 1 | 2016 | 244 | 0.420 |
Why?
|
| Prenatal Diagnosis | 6 | 2008 | 24 | 0.420 |
Why?
|
| Seizures | 2 | 2016 | 64 | 0.420 |
Why?
|
| Transients and Migrants | 1 | 2016 | 297 | 0.410 |
Why?
|
| Proteinuria | 1 | 2012 | 59 | 0.410 |
Why?
|
| North Carolina | 4 | 2019 | 1538 | 0.410 |
Why?
|
| Pregnancy Trimester, Second | 9 | 2016 | 23 | 0.400 |
Why?
|
| Down Syndrome | 5 | 2010 | 14 | 0.400 |
Why?
|
| Streptococcal Infections | 3 | 2011 | 22 | 0.400 |
Why?
|
| Uterine Cervical Neoplasms | 2 | 2013 | 36 | 0.390 |
Why?
|
| Oxygen Inhalation Therapy | 1 | 2011 | 9 | 0.390 |
Why?
|
| Infant | 5 | 2020 | 1061 | 0.390 |
Why?
|
| Pregnancy Complications, Infectious | 3 | 2009 | 32 | 0.380 |
Why?
|
| Treatment Outcome | 9 | 2017 | 3304 | 0.380 |
Why?
|
| Vaginal Smears | 1 | 2011 | 9 | 0.380 |
Why?
|
| Precancerous Conditions | 1 | 2011 | 27 | 0.370 |
Why?
|
| Odds Ratio | 8 | 2017 | 472 | 0.360 |
Why?
|
| Fetofetal Transfusion | 1 | 2010 | 2 | 0.360 |
Why?
|
| Abortion, Spontaneous | 4 | 2013 | 12 | 0.350 |
Why?
|
| Twins, Monozygotic | 1 | 2010 | 14 | 0.350 |
Why?
|
| Birth Weight | 4 | 2014 | 47 | 0.350 |
Why?
|
| Fetal Diseases | 3 | 2009 | 19 | 0.350 |
Why?
|
| Maternal Mortality | 2 | 2020 | 12 | 0.340 |
Why?
|
| Hispanic Americans | 1 | 2016 | 940 | 0.340 |
Why?
|
| Diabetes, Gestational | 3 | 2020 | 24 | 0.320 |
Why?
|
| Time Factors | 11 | 2020 | 2145 | 0.320 |
Why?
|
| Abnormalities, Multiple | 1 | 2008 | 28 | 0.310 |
Why?
|
| Severity of Illness Index | 4 | 2020 | 881 | 0.310 |
Why?
|
| Streptococcus agalactiae | 2 | 2004 | 5 | 0.300 |
Why?
|
| ROC Curve | 11 | 2013 | 163 | 0.300 |
Why?
|
| Forecasting | 3 | 2010 | 142 | 0.290 |
Why?
|
| Male | 12 | 2020 | 19202 | 0.280 |
Why?
|
| Prenatal Care | 3 | 2017 | 51 | 0.270 |
Why?
|
| Predictive Value of Tests | 13 | 2020 | 873 | 0.270 |
Why?
|
| Prospective Studies | 9 | 2015 | 2282 | 0.270 |
Why?
|
| Apgar Score | 2 | 2016 | 8 | 0.260 |
Why?
|
| Abruptio Placentae | 4 | 2008 | 7 | 0.250 |
Why?
|
| Seroma | 2 | 2015 | 5 | 0.250 |
Why?
|
| Rhabdomyoma | 1 | 2005 | 3 | 0.250 |
Why?
|
| Obstetric Labor, Premature | 5 | 2009 | 10 | 0.250 |
Why?
|
| Tuberous Sclerosis | 1 | 2005 | 8 | 0.250 |
Why?
|
| Registries | 2 | 2017 | 298 | 0.250 |
Why?
|
| Heart Neoplasms | 1 | 2005 | 18 | 0.240 |
Why?
|
| Pregnancy, Ectopic | 1 | 2004 | 8 | 0.240 |
Why?
|
| Hospitals, Military | 1 | 2004 | 11 | 0.240 |
Why?
|
| Escherichia coli | 1 | 2004 | 87 | 0.230 |
Why?
|
| Escherichia coli Infections | 1 | 2004 | 39 | 0.230 |
Why?
|
| Abdominal Wall | 2 | 2016 | 22 | 0.230 |
Why?
|
| Respiratory Distress Syndrome, Newborn | 3 | 2016 | 11 | 0.230 |
Why?
|
| Glucose Tolerance Test | 1 | 2004 | 126 | 0.230 |
Why?
|
| Electrosurgery | 2 | 2013 | 5 | 0.220 |
Why?
|
| Sickle Cell Trait | 1 | 2003 | 14 | 0.210 |
Why?
|
| Infant, Premature | 4 | 2019 | 69 | 0.210 |
Why?
|
| Prognosis | 2 | 2006 | 1496 | 0.210 |
Why?
|
| Suture Techniques | 2 | 2014 | 61 | 0.210 |
Why?
|
| Sensitivity and Specificity | 11 | 2010 | 581 | 0.210 |
Why?
|
| Quality-Adjusted Life Years | 3 | 2018 | 31 | 0.200 |
Why?
|
| Amniocentesis | 4 | 2009 | 6 | 0.200 |
Why?
|
| Maternal Welfare | 2 | 2014 | 8 | 0.200 |
Why?
|
| Labor, Obstetric | 2 | 2020 | 36 | 0.190 |
Why?
|
| Spinal Dysraphism | 2 | 2012 | 3 | 0.190 |
Why?
|
| Cleft Lip | 2 | 2012 | 15 | 0.180 |
Why?
|
| Amniotic Fluid | 2 | 2016 | 86 | 0.180 |
Why?
|
| Cleft Palate | 2 | 2012 | 24 | 0.180 |
Why?
|
| African Americans | 4 | 2008 | 1424 | 0.180 |
Why?
|
| Risk | 3 | 2017 | 321 | 0.180 |
Why?
|
| Humerus | 2 | 2010 | 32 | 0.180 |
Why?
|
| Oxytocics | 3 | 2012 | 13 | 0.180 |
Why?
|
| Missouri | 8 | 2012 | 21 | 0.170 |
Why?
|
| Femur | 2 | 2010 | 74 | 0.170 |
Why?
|
| Anticonvulsants | 2 | 2012 | 65 | 0.170 |
Why?
|
| Cervical Ripening | 1 | 2019 | 2 | 0.170 |
Why?
|
| Pennsylvania | 5 | 2008 | 82 | 0.170 |
Why?
|
| Hernia, Umbilical | 2 | 2009 | 2 | 0.170 |
Why?
|
| Gastroschisis | 2 | 2009 | 3 | 0.170 |
Why?
|
| Parity | 5 | 2013 | 20 | 0.170 |
Why?
|
| Heart Defects, Congenital | 3 | 2009 | 31 | 0.160 |
Why?
|
| Sterilization, Reproductive | 1 | 2018 | 1 | 0.160 |
Why?
|
| Fetal Death | 3 | 2009 | 9 | 0.160 |
Why?
|
| Tobacco | 1 | 2019 | 57 | 0.160 |
Why?
|
| Fetal Membranes, Premature Rupture | 2 | 2008 | 13 | 0.160 |
Why?
|
| Nasal Bone | 2 | 2008 | 5 | 0.160 |
Why?
|
| Safety | 2 | 2016 | 77 | 0.150 |
Why?
|
| Obstetrics | 2 | 2015 | 26 | 0.150 |
Why?
|
| Intensive Care Units, Neonatal | 2 | 2016 | 33 | 0.150 |
Why?
|
| Sepsis | 2 | 2016 | 161 | 0.140 |
Why?
|
| Combined Modality Therapy | 1 | 2018 | 560 | 0.140 |
Why?
|
| Meconium Aspiration Syndrome | 1 | 2016 | 1 | 0.140 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2014 | 629 | 0.140 |
Why?
|
| Hypoxia-Ischemia, Brain | 1 | 2016 | 3 | 0.140 |
Why?
|
| Term Birth | 1 | 2016 | 5 | 0.140 |
Why?
|
| Pelvimetry | 2 | 2013 | 2 | 0.140 |
Why?
|
| Drug Administration Schedule | 2 | 2014 | 276 | 0.140 |
Why?
|
| Nicotine | 1 | 2019 | 174 | 0.140 |
Why?
|
| Intensive Care Units | 1 | 2017 | 111 | 0.140 |
Why?
|
| Cardiopulmonary Resuscitation | 1 | 2016 | 24 | 0.140 |
Why?
|
| Vagina | 1 | 2016 | 59 | 0.140 |
Why?
|
| Perinatal Mortality | 1 | 2016 | 3 | 0.130 |
Why?
|
| Patient Preference | 1 | 2016 | 47 | 0.130 |
Why?
|
| Enterocolitis, Necrotizing | 1 | 2016 | 27 | 0.130 |
Why?
|
| Respiration, Artificial | 1 | 2016 | 98 | 0.130 |
Why?
|
| Pregnancy in Diabetics | 3 | 2020 | 6 | 0.130 |
Why?
|
| Maternal Age | 4 | 2009 | 15 | 0.130 |
Why?
|
| Medical Records | 3 | 2005 | 76 | 0.120 |
Why?
|
| Fetal Blood | 1 | 2015 | 38 | 0.120 |
Why?
|
| Intensive Care, Neonatal | 1 | 2014 | 9 | 0.120 |
Why?
|
| Infusions, Intravenous | 1 | 2014 | 100 | 0.120 |
Why?
|
| Patient Readmission | 1 | 2015 | 126 | 0.120 |
Why?
|
| Confidence Intervals | 1 | 2014 | 149 | 0.120 |
Why?
|
| Recurrence | 4 | 2008 | 263 | 0.120 |
Why?
|
| Uterine Cervical Dysplasia | 1 | 2013 | 3 | 0.120 |
Why?
|
| Pelvic Bones | 1 | 2013 | 32 | 0.110 |
Why?
|
| Cephalometry | 1 | 2012 | 19 | 0.110 |
Why?
|
| Fructose | 1 | 2012 | 11 | 0.100 |
Why?
|
| Aneuploidy | 2 | 2009 | 10 | 0.100 |
Why?
|
| Pelvis | 1 | 2013 | 61 | 0.100 |
Why?
|
| Probability | 3 | 2007 | 159 | 0.100 |
Why?
|
| Models, Statistical | 2 | 2020 | 175 | 0.100 |
Why?
|
| Fetal Monitoring | 2 | 2009 | 5 | 0.100 |
Why?
|
| Twins | 3 | 2009 | 7 | 0.100 |
Why?
|
| Creatinine | 1 | 2012 | 196 | 0.100 |
Why?
|
| Head | 1 | 2012 | 51 | 0.100 |
Why?
|
| Umbilical Arteries | 2 | 2009 | 2 | 0.100 |
Why?
|
| Amnion | 1 | 2012 | 37 | 0.100 |
Why?
|
| Cefazolin | 1 | 2011 | 1 | 0.100 |
Why?
|
| Periodontal Attachment Loss | 1 | 2011 | 1 | 0.100 |
Why?
|
| Infant, Low Birth Weight | 1 | 2011 | 11 | 0.100 |
Why?
|
| Vaginosis, Bacterial | 1 | 2011 | 7 | 0.100 |
Why?
|
| Clindamycin | 1 | 2011 | 22 | 0.100 |
Why?
|
| Fetus | 2 | 2010 | 86 | 0.100 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2011 | 37 | 0.100 |
Why?
|
| Prenatal Exposure Delayed Effects | 1 | 2012 | 92 | 0.100 |
Why?
|
| Surgical Flaps | 1 | 2012 | 72 | 0.100 |
Why?
|
| Adolescent | 8 | 2013 | 3568 | 0.100 |
Why?
|
| Infant, Small for Gestational Age | 1 | 2011 | 5 | 0.100 |
Why?
|
| Nuchal Translucency Measurement | 2 | 2008 | 2 | 0.100 |
Why?
|
| Sleep Apnea, Obstructive | 1 | 2011 | 58 | 0.100 |
Why?
|
| Lacerations | 1 | 2011 | 9 | 0.100 |
Why?
|
| Endometrial Ablation Techniques | 1 | 2011 | 4 | 0.100 |
Why?
|
| Hydrotherapy | 1 | 2011 | 4 | 0.100 |
Why?
|
| Perineum | 1 | 2011 | 18 | 0.100 |
Why?
|
| Menorrhagia | 1 | 2011 | 4 | 0.100 |
Why?
|
| Smoking | 2 | 2019 | 528 | 0.090 |
Why?
|
| Estriol | 3 | 2006 | 4 | 0.090 |
Why?
|
| alpha-Fetoproteins | 3 | 2006 | 10 | 0.090 |
Why?
|
| Paired Box Transcription Factors | 1 | 2011 | 5 | 0.090 |
Why?
|
| Bariatric Surgery | 1 | 2011 | 26 | 0.090 |
Why?
|
| Genes, Wilms Tumor | 1 | 2011 | 6 | 0.090 |
Why?
|
| Sutures | 1 | 2011 | 20 | 0.090 |
Why?
|
| Sample Size | 1 | 2011 | 38 | 0.090 |
Why?
|
| Cadherins | 1 | 2011 | 26 | 0.090 |
Why?
|
| Pregnancy Complications, Cardiovascular | 1 | 2011 | 25 | 0.090 |
Why?
|
| Genetic Markers | 1 | 2011 | 124 | 0.090 |
Why?
|
| Emergency Service, Hospital | 1 | 2014 | 467 | 0.090 |
Why?
|
| Fetal Weight | 1 | 2010 | 6 | 0.090 |
Why?
|
| Progestins | 2 | 2010 | 22 | 0.090 |
Why?
|
| Sacrococcygeal Region | 1 | 2010 | 6 | 0.090 |
Why?
|
| Urinary Bladder | 2 | 2010 | 182 | 0.090 |
Why?
|
| Urodynamics | 1 | 2010 | 37 | 0.090 |
Why?
|
| Laser Coagulation | 1 | 2010 | 13 | 0.090 |
Why?
|
| Tobacco, Smokeless | 1 | 2010 | 15 | 0.090 |
Why?
|
| Reproducibility of Results | 3 | 2010 | 765 | 0.090 |
Why?
|
| Lung | 1 | 2011 | 249 | 0.090 |
Why?
|
| Regression Analysis | 2 | 2010 | 292 | 0.090 |
Why?
|
| DNA Methylation | 1 | 2011 | 141 | 0.090 |
Why?
|
| Oligohydramnios | 1 | 2009 | 1 | 0.080 |
Why?
|
| Cytomegalovirus Infections | 1 | 2009 | 48 | 0.080 |
Why?
|
| Progesterone | 1 | 2010 | 101 | 0.080 |
Why?
|
| Heart Rate, Fetal | 1 | 2009 | 8 | 0.080 |
Why?
|
| Urinary Incontinence, Stress | 1 | 2010 | 65 | 0.080 |
Why?
|
| Bradycardia | 1 | 2009 | 16 | 0.080 |
Why?
|
| Urologic Surgical Procedures | 1 | 2010 | 64 | 0.080 |
Why?
|
| Models, Biological | 1 | 2011 | 392 | 0.080 |
Why?
|
| Incidental Findings | 1 | 2009 | 25 | 0.080 |
Why?
|
| Follow-Up Studies | 1 | 2014 | 2263 | 0.080 |
Why?
|
| Hypertension, Pregnancy-Induced | 1 | 2009 | 13 | 0.080 |
Why?
|
| Anti-Bacterial Agents | 1 | 2011 | 322 | 0.080 |
Why?
|
| Chorionic Villi Sampling | 1 | 2008 | 3 | 0.080 |
Why?
|
| Research Design | 1 | 2011 | 315 | 0.080 |
Why?
|
| Hernia, Diaphragmatic | 1 | 2008 | 3 | 0.080 |
Why?
|
| Socioeconomic Factors | 2 | 2008 | 429 | 0.080 |
Why?
|
| Tracheoesophageal Fistula | 1 | 2008 | 5 | 0.080 |
Why?
|
| Chromosome Aberrations | 1 | 2008 | 23 | 0.080 |
Why?
|
| Fatal Outcome | 2 | 2006 | 83 | 0.080 |
Why?
|
| Genetics, Population | 1 | 2008 | 32 | 0.080 |
Why?
|
| Continental Population Groups | 1 | 2010 | 237 | 0.080 |
Why?
|
| Central Nervous System | 1 | 2008 | 43 | 0.080 |
Why?
|
| Hyperthermia, Induced | 1 | 2011 | 241 | 0.080 |
Why?
|
| Lactation | 1 | 2008 | 16 | 0.080 |
Why?
|
| DNA, Bacterial | 2 | 2004 | 27 | 0.080 |
Why?
|
| Birth Intervals | 1 | 2007 | 1 | 0.080 |
Why?
|
| Monte Carlo Method | 1 | 2007 | 18 | 0.070 |
Why?
|
| Multiple Trauma | 1 | 2008 | 41 | 0.070 |
Why?
|
| Echocardiography | 2 | 2006 | 158 | 0.070 |
Why?
|
| Placenta Previa | 1 | 2007 | 2 | 0.070 |
Why?
|
| Epidemiologic Studies | 1 | 2007 | 20 | 0.070 |
Why?
|
| Chylothorax | 1 | 2006 | 1 | 0.070 |
Why?
|
| Lymphangiectasis | 1 | 2006 | 5 | 0.070 |
Why?
|
| Pleural Effusion | 1 | 2006 | 12 | 0.070 |
Why?
|
| Hospitals | 1 | 2007 | 102 | 0.070 |
Why?
|
| Hydroxyprogesterones | 1 | 2006 | 4 | 0.070 |
Why?
|
| Databases, Factual | 3 | 2020 | 354 | 0.070 |
Why?
|
| Lung Diseases | 1 | 2006 | 46 | 0.070 |
Why?
|
| Middle Aged | 4 | 2016 | 11834 | 0.070 |
Why?
|
| Polymorphism, Genetic | 1 | 2007 | 184 | 0.070 |
Why?
|
| Thrombophilia | 1 | 2005 | 7 | 0.070 |
Why?
|
| Bandages | 1 | 2005 | 33 | 0.060 |
Why?
|
| European Continental Ancestry Group | 2 | 2008 | 1165 | 0.060 |
Why?
|
| Healthcare Disparities | 1 | 2008 | 169 | 0.060 |
Why?
|
| Herpes Genitalis | 1 | 2005 | 1 | 0.060 |
Why?
|
| Likelihood Functions | 3 | 2010 | 48 | 0.060 |
Why?
|
| Venous Thrombosis | 1 | 2005 | 49 | 0.060 |
Why?
|
| Hydrops Fetalis | 1 | 2005 | 1 | 0.060 |
Why?
|
| Heparin | 1 | 2005 | 73 | 0.060 |
Why?
|
| Fibrinolytic Agents | 1 | 2005 | 70 | 0.060 |
Why?
|
| Hospitals, Packaged | 1 | 2004 | 1 | 0.060 |
Why?
|
| Iraq | 1 | 2004 | 2 | 0.060 |
Why?
|
| Prevalence | 2 | 2009 | 989 | 0.060 |
Why?
|
| DNA Primers | 1 | 2004 | 91 | 0.060 |
Why?
|
| Mass Screening | 1 | 2007 | 263 | 0.060 |
Why?
|
| Polymerase Chain Reaction | 1 | 2004 | 198 | 0.060 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2004 | 263 | 0.060 |
Why?
|
| False Positive Reactions | 1 | 2004 | 29 | 0.060 |
Why?
|
| Hypertension | 1 | 2011 | 961 | 0.060 |
Why?
|
| Philadelphia | 1 | 2003 | 6 | 0.050 |
Why?
|
| Aged | 1 | 2016 | 10308 | 0.050 |
Why?
|
| Radiography | 2 | 2013 | 374 | 0.050 |
Why?
|
| Algorithms | 1 | 2004 | 496 | 0.050 |
Why?
|
| Stillbirth | 2 | 2011 | 7 | 0.050 |
Why?
|
| Streptococcus | 1 | 2020 | 8 | 0.050 |
Why?
|
| Triage | 1 | 2020 | 71 | 0.040 |
Why?
|
| Trisomy | 2 | 2009 | 11 | 0.040 |
Why?
|
| Nebulizers and Vaporizers | 1 | 2019 | 11 | 0.040 |
Why?
|
| Pregnancy Trimester, First | 2 | 2011 | 9 | 0.040 |
Why?
|
| Comorbidity | 1 | 2020 | 566 | 0.040 |
Why?
|
| Reference Values | 2 | 2010 | 246 | 0.040 |
Why?
|
| Cicatrix | 1 | 2016 | 39 | 0.030 |
Why?
|
| Sex Factors | 2 | 2010 | 667 | 0.030 |
Why?
|
| Ultrasonography, Doppler | 2 | 2007 | 24 | 0.030 |
Why?
|
| Perinatal Care | 1 | 2015 | 3 | 0.030 |
Why?
|
| Pain, Postoperative | 1 | 2016 | 178 | 0.030 |
Why?
|
| Incidence | 2 | 2008 | 1199 | 0.030 |
Why?
|
| Nomograms | 1 | 2013 | 32 | 0.030 |
Why?
|
| Cervical Intraepithelial Neoplasia | 1 | 2013 | 4 | 0.030 |
Why?
|
| Postpartum Period | 1 | 2013 | 33 | 0.030 |
Why?
|
| Misoprostol | 1 | 2012 | 5 | 0.030 |
Why?
|
| Drug Therapy, Combination | 1 | 2012 | 288 | 0.020 |
Why?
|
| Fever | 1 | 2011 | 60 | 0.020 |
Why?
|
| Urinary Tract Infections | 1 | 2011 | 45 | 0.020 |
Why?
|
| Cephalopelvic Disproportion | 1 | 2011 | 1 | 0.020 |
Why?
|
| Uterine Artery | 1 | 2010 | 5 | 0.020 |
Why?
|
| Mathematics | 1 | 2010 | 9 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2011 | 483 | 0.020 |
Why?
|
| Anthropometry | 1 | 2010 | 83 | 0.020 |
Why?
|
| Colon | 1 | 2010 | 51 | 0.020 |
Why?
|
| Ureter | 1 | 2010 | 38 | 0.020 |
Why?
|
| Administration, Intravaginal | 1 | 2010 | 9 | 0.020 |
Why?
|
| Models, Economic | 1 | 2009 | 19 | 0.020 |
Why?
|
| Anemia | 1 | 2010 | 58 | 0.020 |
Why?
|
| Deceleration | 1 | 2009 | 1 | 0.020 |
Why?
|
| Placenta | 1 | 2010 | 74 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 13 | 1 | 2008 | 5 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 18 | 1 | 2008 | 7 | 0.020 |
Why?
|
| Hysterotomy | 1 | 2008 | 2 | 0.020 |
Why?
|
| Medical Audit | 1 | 2008 | 15 | 0.020 |
Why?
|
| Siblings | 1 | 2008 | 25 | 0.020 |
Why?
|
| Urban Population | 1 | 2009 | 89 | 0.020 |
Why?
|
| Hospitals, University | 1 | 2008 | 30 | 0.020 |
Why?
|
| Hospitals, Community | 1 | 2008 | 12 | 0.020 |
Why?
|
| Prejudice | 1 | 2008 | 49 | 0.020 |
Why?
|
| Injury Severity Score | 1 | 2008 | 113 | 0.020 |
Why?
|
| Health Status Disparities | 1 | 2008 | 131 | 0.020 |
Why?
|
| Chorionic Gonadotropin | 1 | 2006 | 13 | 0.020 |
Why?
|
| Proportional Hazards Models | 1 | 2008 | 753 | 0.020 |
Why?
|
| New England | 1 | 2006 | 3 | 0.020 |
Why?
|
| Secondary Prevention | 1 | 2006 | 63 | 0.020 |
Why?
|
| Chorionic Gonadotropin, beta Subunit, Human | 1 | 2005 | 3 | 0.020 |
Why?
|
| Technology Assessment, Biomedical | 1 | 2005 | 11 | 0.020 |
Why?
|
| Inhibins | 1 | 2005 | 4 | 0.020 |
Why?
|
| Pulsatile Flow | 1 | 2005 | 26 | 0.020 |
Why?
|
| Middle Cerebral Artery | 1 | 2005 | 13 | 0.020 |
Why?
|
| Herpesvirus 2, Human | 1 | 2005 | 2 | 0.020 |
Why?
|
| Virus Shedding | 1 | 2005 | 5 | 0.020 |
Why?
|
| Thromboembolism | 1 | 2005 | 34 | 0.020 |
Why?
|
| Herpesvirus 1, Human | 1 | 2005 | 8 | 0.020 |
Why?
|
| Health Care Costs | 1 | 2006 | 118 | 0.020 |
Why?
|
| Treatment Failure | 1 | 2005 | 162 | 0.020 |
Why?
|
| Postoperative Care | 1 | 2005 | 76 | 0.020 |
Why?
|
| Antibodies, Viral | 1 | 2005 | 58 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2005 | 129 | 0.020 |
Why?
|
| Biophysics | 1 | 2004 | 11 | 0.020 |
Why?
|
| Biophysical Phenomena | 1 | 2004 | 6 | 0.020 |
Why?
|
| Laser-Doppler Flowmetry | 1 | 2004 | 31 | 0.020 |
Why?
|
| Electrophoresis, Agar Gel | 1 | 2004 | 14 | 0.020 |
Why?
|
| Blotting, Southern | 1 | 2004 | 24 | 0.020 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2006 | 251 | 0.020 |
Why?
|
| Age Factors | 1 | 2008 | 1187 | 0.010 |
Why?
|
| Base Sequence | 1 | 2004 | 252 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 2004 | 357 | 0.010 |
Why?
|
| Hospitalization | 1 | 2006 | 468 | 0.010 |
Why?
|
| Patient Satisfaction | 1 | 2005 | 240 | 0.010 |
Why?
|